PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 20, 2026Advanced Composites and Hybrid MaterialsOpen Access

Nano-engineered precision strategies for hematological malignancies: current advances and translational roadmap

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZhongsong ZhangJCJunhao ChenQSQi Shi

Discussion

Loading...

Member takes

Overview

Review highlights advances in nanomedicine to tackle treatment challenges in hematological malignancies, suggesting clinical pathways.

Key Points

  • This review aims to explore how nanomedicine can address challenges in treating hematological malignancies (HMs) like drug resistance and toxicity.
  • Categorized and summarized five classes of nanoplatforms: inorganic, polymeric, hybrid, biogenic, and stimuli-responsive.
  • Discussed key advances and clinical translation barriers in nanomedicine for HMs.
  • Proposed solutions for scalable manufacturing and clinical validation, including AI-driven design.
  • Nanomaterials enhance treatment efficacy, disease monitoring, and theranostic applications in HMs.
  • Integration of multiple functionalities in nanocarriers improves site-specific drug release within the tumor microenvironment.
  • Barriers to clinical translation include manufacturing and regulatory issues, with proposed solutions to overcome these challenges.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4f19f03e14405aa9a459https://doi.org/10.1007/s42114-026-01846-z
View Full Paper
Ask AI
Bookmark
Share